1. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
- Author
-
Thierry Lesimple, Alain Ravaud, Claude Linassier, A. Caty, Jean-Marc Ferrero, Bruno Audhuy, Drevon M, Lionnel Geoffrois, J.-Y. Douillard, Sylvie Negrier, Christine Chevreau, Frédéric Gomez, and Bernard Escudier
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Injections, Subcutaneous ,medicine.medical_treatment ,Alpha interferon ,Interferon alpha-2 ,Gastroenterology ,Renal cell carcinoma ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Infusions, Intravenous ,Carcinoma, Renal Cell ,Interferon alfa ,Aged ,Kidney ,Chemotherapy ,business.industry ,Interferon-alpha ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Recombinant Proteins ,Surgery ,Survival Rate ,Regimen ,medicine.anatomical_structure ,Oncology ,Fluorouracil ,Interleukin-2 ,Female ,business ,medicine.drug ,Kidney disease - Abstract
PURPOSE A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS One hundred eleven patients were included. Patients received subcutaneous IL-2 9 x 10(6) IU daily for 6 days and IFNalpha 6 x 10(6) IU on days 1, 3, and 5 every other week for 8 weeks. 5-FU was administered through a continuous infusion at 600 mg/m2 for 5 consecutive days for 1 week every 4 weeks. RESULTS The response rate was 1.8% (95% confidence interval [CI], 0% to 4.3%) with only two partial responses (PRs). Toxicity was moderate with 3.6% grade 4 events and two deaths related to treatment. CONCLUSION This regimen of IL-2, IFNalpha, and 5-FU in patients with metastatic renal cell carcinoma was ineffective. The results raise the question of the dose and schedule of subcutaneous cytokines that must be used in metastatic renal carcinoma.
- Published
- 1998